

CORRIGENDUM

A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group

G Barosi, C Besses, G Birgegard, J Briere, F Cervantes, G Finazzi, H Gisslinger, M Griesshammer, L Gugliotta, C Harrison, H Hasselbalch, E Lengfelder, JT Reilly, JJ Michiels and T Barbui

Leukemia (2007) 21, 1136. doi:10.1038/sj.leu.2404665

Correction to: *Leukemia* (2007) 21, 277–280.

doi:10.1038/sj.leu.2404473

It has been identified by the authors that there is an error in Table 2.

The correct Table 2 is shown below:

The authors apologize for any inconvenience caused.

Table 2

Platelet count > 600 000 μ l after 3 months of at least 2 g/day of HU (2.5 g/day in patients with a body weight > 80 kg)

Platelet count > 400 000 μ l and WBC less than 2500 μ l at any dose of HU

Platelet count > 400 000 μ l and Hb less than 10 g/dl at any dose of HU

Presence of leg ulcers or other unacceptable muco-cutaneous manifestations at any dose of HU

HU-related fever

Abbreviations: ET, essential thrombocythemia; HU, hydroxyurea; WBC, white blood cells.